Adaptive Biotechnologies - ADPT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.80
  • Forecasted Upside: 125.91%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.01
▲ +0.39 (14.89%)

This chart shows the closing price for ADPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adaptive Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADPT

Analyst Price Target is $6.80
▲ +125.91% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. The average price target is $6.80, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 125.91% upside from the last price of $3.01.

This chart shows the closing price for ADPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Adaptive Biotechnologies. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2024BTIG ResearchLower TargetBuy ➝ Buy$6.00 ➝ $5.00Low
2/16/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$11.00 ➝ $5.00Low
2/15/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$11.00 ➝ $8.00Low
11/13/2023Piper SandlerLower TargetOverweight ➝ Overweight$13.00 ➝ $6.00Low
11/10/2023William BlairReiterated RatingOutperformLow
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $10.00Low
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$14.00 ➝ $13.00Low
8/8/2023Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $14.00Low
8/4/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00Low
5/8/2023Piper SandlerBoost Target$14.00 ➝ $15.00Low
2/16/2023Morgan StanleyLower TargetEqual Weight$16.00 ➝ $15.00Low
2/15/2023Credit Suisse GroupReiterated RatingUnderperform$7.00Low
1/4/2023ScotiabankInitiated CoverageSector Outperform$15.00Low
12/21/2022Piper SandlerUpgradeNeutral ➝ Overweight$7.50 ➝ $14.00Low
11/7/2022Morgan StanleyLower TargetEqual Weight$17.00 ➝ $16.00Low
10/26/2022Piper SandlerLower TargetNeutral$12.00 ➝ $7.50Low
8/24/2022Credit Suisse GroupInitiated CoverageUnderperform$8.00Low
8/17/2022Piper SandlerBoost TargetNeutral$7.50 ➝ $12.00Low
8/9/2022BTIG ResearchLower Target$17.00N/A
6/2/2022Piper SandlerInitiated CoverageNeutral$7.50High
5/24/2022The Goldman Sachs GroupLower TargetNeutral$14.00 ➝ $10.00Low
2/16/2022Bank of AmericaLower TargetBuy$40.00 ➝ $32.00High
2/16/2022JPMorgan Chase & Co.Lower TargetOverweight$75.00 ➝ $50.00High
2/16/2022The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$54.00 ➝ $21.00High
2/16/2022BTIG ResearchLower TargetBuy$35.00 ➝ $30.00High
2/15/2022Morgan StanleyLower TargetEqual Weight$46.00 ➝ $27.00Low
1/11/2022BTIG ResearchLower Target$55.00 ➝ $45.00Low
10/15/2021William BlairReiterated RatingOutperformHigh
10/15/2021CowenInitiated CoverageOutperformLow
8/6/2021The Goldman Sachs GroupLower TargetNeutral$59.00 ➝ $52.00High
5/7/2021Morgan StanleyLower TargetEqual Weight$60.00 ➝ $55.00High
3/9/2021The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$74.00 ➝ $63.00High
3/3/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$74.00 ➝ $63.00High
2/26/2021Morgan StanleyBoost TargetEqual Weight$46.00 ➝ $60.00Medium
1/19/2021BTIG ResearchBoost TargetPositive ➝ Buy$66.00 ➝ $74.00Low
11/12/2020BTIG ResearchBoost TargetBuy$60.00 ➝ $63.00High
11/11/2020JPMorgan Chase & Co.Reiterated RatingOverweight$50.00 ➝ $60.00High
11/11/2020Morgan StanleyBoost TargetEqual Weight$42.00 ➝ $46.00High
10/7/2020BTIG ResearchInitiated CoverageBuyLow
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$42.00High
8/11/2020William BlairReiterated RatingOutperformMedium
6/3/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00Low
5/19/2020GuggenheimBoost TargetBuy$44.00 ➝ $50.00Low
4/17/2020BTIG ResearchReiterated RatingBuy$46.00High
7/23/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$46.00Medium
7/22/2019William BlairInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019GuggenheimInitiated CoverageBuy ➝ Buy$47.00High
7/22/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$45.00High
7/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight$45.00High
7/22/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$32.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/17/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/17/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/16/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/14/2024
  • 8 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
3/15/2024
  • 6 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 6 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Adaptive Biotechnologies logo
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $3.01
Low: $2.55
High: $3.10

50 Day Range

MA: $3.47
Low: $2.58
High: $4.27

52 Week Range

Now: $3.01
Low: $2.53
High: $9.08

Volume

6,505,403 shs

Average Volume

1,506,339 shs

Market Capitalization

$436.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Adaptive Biotechnologies?

The following sell-side analysts have issued reports on Adaptive Biotechnologies in the last twelve months: BTIG Research, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for ADPT.

What is the current price target for Adaptive Biotechnologies?

5 Wall Street analysts have set twelve-month price targets for Adaptive Biotechnologies in the last year. Their average twelve-month price target is $6.80, suggesting a possible upside of 125.9%. Morgan Stanley has the highest price target set, predicting ADPT will reach $10.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $5.00 for Adaptive Biotechnologies in the next year.
View the latest price targets for ADPT.

What is the current consensus analyst rating for Adaptive Biotechnologies?

Adaptive Biotechnologies currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ADPT.

What other companies compete with Adaptive Biotechnologies?

How do I contact Adaptive Biotechnologies' investor relations team?

Adaptive Biotechnologies' physical mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The company's listed phone number is (206) 659-0067 and its investor relations email address is [email protected]. The official website for Adaptive Biotechnologies is www.constructionpartners.net. Learn More about contacing Adaptive Biotechnologies investor relations.